Hodnocení topické aplikace BMX-010 u pacientů s růžovkou
Průzkumná zkouška k vyhodnocení klinické účinnosti topické aplikace BMX-010 u pacientů s růžovkou
This is an exploratory Phase 2 trial of BMX-010 in patients with Rosacea which will be conducted in two parts. Up to 210 subjects with Rosacea will be enrolled.
Přehled studie
Postavení
Postavení
Podmínky
Podmínky
Intervence / Léčba
Intervence / Léčba
Detailní popis
Part A is designed to confirm the optimal formulation, strength, and dosing frequency of the study drug. Up to 60 subjects will be enrolled in this part.
Part B is designed to be a randomized, double-blind trial studying the optimal formulation, strength, and dosing frequency of BMX-010 as determined in Part A, compared to Placebo. Up to 150 subjects will be enrolled in this part.
In both parts, adult subjects with Rosacea will be enrolled.
Typ studie
Typ studie
Zápis (Aktuální)
Zápis
Fáze
Fáze
- Fáze 2
Kontakty a umístění
Studijní místa
-
-
Colorado
-
Englewood, Colorado, Spojené státy, 80113
- Colorado Skin Care
-
-
Kritéria účasti
Kritéria způsobilosti
Kritéria způsobilosti
Věk způsobilý ke studiu
Přijímá zdravé dobrovolníky
Pohlaví způsobilá ke studiu
Popis
Inclusion Criteria:
- Male or female, at least 18 years of age;
- A clinical diagnosis of mild to severe facial rosacea;
- Screening and Baseline IGA score > 2 (greater than or equal to 2);
- A minimum Clinician Erythema Assessment (CEA) score of 2 at Screening and at Baseline Visits (prior to the investigational product application);
- Willing to refrain from using any topical or systemic treatments for inflammatory skin disease, other than the investigational product;
- Candidate for topical treatment of Rosacea;
- If a cleanser, moisturizer or sunscreen is needed during the study, Subjects must be willing to use only allowed cleansers, moisturizers, sunscreens, or moisturizer/sunscreen combination products. If the subject wears makeup they must agree to use non-comedogenic makeup;
- Females of child-bearing potential must have a negative urine pregnancy test within 48 hours prior to the first drug administration;
- Females of child-bearing potential must be willing to use 2 methods of contraception deemed adequate by the investigator (for example, oral contraceptive pills plus a barrier method) through the trial and for 1 month thereafter to be eligible for, and continue participation in, the study;
- Ability to complete the study in compliance with the protocol, including agreement in writing to apply study product only to the assigned areas; and
- Ability to understand and provide written informed consent.
Exclusion Criteria:
- Any dermatological conditions on the face that could interfere with clinical evaluations;
- Any underlying disease(s) or some other dermatological condition of the face that requires the use of interfering topical or systemic therapy or makes evaluations and lesion count inconclusive;
- Presence of beard or excessive facial hair at Screening which would interfere with the study treatments or study assessments and refusal to remove for duration of study;
- Subjects with any underlying disease that the Investigator deems uncontrolled, and poses a concern for the subject's safety while participating in the study;
- Concomitant skin disease that could confound clinical evaluations or increase risk to the subject;
- Use of medicated make-up (including anti-aging make-up) throughout the study;
- Use during the study of 1) systemic steroids, 2) topical retinoids to the face, 3) antibiotics known to impact rosacea, 4) immunosuppressive agents, or immunomodulators;
- Facial use of 1) topical steroids, 2) topical anti-inflammatory agents, 3) topical antimycotics, 4) any topical rosacea treatments or 4) topical antibiotics;
- Use of medicated cleansers on the face (throughout the study);
- Use of topical astringents or abrasives, medical topical preparations (prescription and OTC products) within 2 days prior to Baseline and throughout the study;
- Systemic or skin infection requiring antimicrobial therapy;
- Systemic chemotherapy or radiotherapy within 4 weeks of the Baseline Visit;
- Immunocompromise of any cause, known human immunodeficiency virus infection, or acquired immunodeficiency syndrome;
- Pregnancy, planned pregnancy, lactation, or inadequate contraception as judged by the investigator;
- Active drug or alcohol dependence;
- Significant acute or chronic medical, neurological, or psychiatric illness that, in the judgment of the investigator, could compromise subject safety, limit the subject's ability to complete the study, and/or compromise the objectives of the study;
- Previous clinical trial participation for the indication being treated in this protocol.
Studijní plán
Jak je studie koncipována?
Detaily designu
- Primární účel: Léčba
- Přidělení: Nerandomizované
- Intervenční model: Paralelní přiřazení
- Maskování: Žádné (otevřený štítek)
Počet zbraní
Zbraně a zásahy
Skupina účastníků / ArmSkupina účastníků / Arm |
Intervence / LéčbaIntervence / Léčba |
|---|---|
|
Experimentální: BMX-010 0.03%
Approximately 30 subjects will receive BMX-010 0.03% for 7-28 days to be applied topically to Rosacea of the face. |
Safety and efficacy of BMX-010 in topical treatment of rosacea. |
|
Experimentální: BMX-010 0.1%
Approximately 30 subjects will receive BMX-010 0.1% for 7-28 days to be applied topically to Rosacea of the face. |
Safety and efficacy of BMX-010 in topical treatment of rosacea. |
Co je měření studie?
Primární výstupní opatření
Primární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Investigator Global Assessment (IGA) Grade: Clinically Meaningful Rosacea Treatment Success Rate
Časové okno: 43 days
|
The percentage of subjects will be reported that experience a clinically meaningful treatment success, which is defined as a 2-point reduction in Investigator Global Assessment (IGA) grade from the baseline assessment prior to treatment to the final assessment two weeks after dosing ends (Day 43). |
43 days
|
|
Clinical Erythema Assessment (CEA): Clinically Meaningful Erythema Reduction Rate
Časové okno: 43 days
|
Assessed by number of participants with at least a 2-point reduction in Clinical Erythema Assessment (CEA) grade from the baseline score prior to treatment to a final assessment two weeks after dosing ends (Day 43). |
43 days
|
|
Investigator Global Assessment (IGA) Grade: Rosacea Severity Change Over Treatment Period
Časové okno: 28 days
|
The Investigator Global Assessment (IGA) grade, which will be assessed weekly, is a clinical assessment of disease severity. Scores range from 0 (clear) - 4 (severe). The change in IGA score from Baseline to 28 days of treatment will be reported. |
28 days
|
|
Clinical Erythema Assessment (CEA): Erythema Severity Change Over Treatment Period
Časové okno: 28 days
|
The Clinical Erythema Assessment (CEA) grade will be assessed weekly. Grades range from 0 = clear/no erythema to 4 = severe/fiery red erythema. The change in CEA score from Baseline to 28 days of treatment will be reported. |
28 days
|
|
Investigator Global Assessment (IGA) Grade: Clinically Meaningful Rosacea Reduction During Treatment
Časové okno: 28 days
|
The percentage of subjects will be reported that experience a clinically meaningful rosacea reduction, which is defined as a 2-point reduction in Investigator Global Assessment (IGA) grade over the treatment period of 28 days. |
28 days
|
Sekundární výstupní opatření
Sekundární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Clinical Photography Documenting Rosacea Symptoms in Patients Treated With BMX-010
Časové okno: 43 days
|
If consented by the patient, photos will be taken at each study visit. The number of patients photographed will be reported. |
43 days
|
|
Change in Number of Inflammatory Papules/Pustules From Baseline to 43 Day Follow-up.
Časové okno: 43 days
|
Inflammatory lesions will be counted at each study visit. The mean percent change in inflammatory papules/pustules counts from baseline to the final (day 43) follow-up will be reported. |
43 days
|
Spolupracovníci a vyšetřovatelé
Sponzor
Sponzor
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia (Aktuální)
Začátek studia
Primární dokončení (Aktuální)
Primární dokončení
Dokončení studie (Aktuální)
Dokončení studie
Termíny zápisu do studia
První předloženo
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Aktuální)
První zveřejněno
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Aktuální)
Poslední zveřejněná aktualizace
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Naposledy ověřeno
Více informací
Termíny související s touto studií
Další relevantní podmínky MeSH
Další identifikační čísla studie
Další identifikační čísla studie
- BMX-DERM-202
Informace o lécích a zařízeních, studijní dokumenty
Studuje lékový produkt regulovaný americkým FDA
Studuje produkt zařízení regulovaný americkým úřadem FDA
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .